Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Sol-Gel Technologies Ltd. (SLGL) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $61.53, with a market capitalisation of $213.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.15 to $97.97. This page covers its latest market performance, valuation, price trends and company information.
$213.40M | |
$64.46 | |
$210.00 | |
$3.34 | |
$64.40 | |
21.52K | |
51.26K | |
-- | |
$97.97 | |
$23.15 | |
-- | |
-- |
Sol-Gel Technologies Ltd. (SLGL) is currently trading at $61.53 as of 2026-09-16 14:39:00, down 4.46% ($2.87) from the previous close of $64.40
During today's regular trading session, SLGL has traded between $3.34 and $210.00, with a trading volume of 21.52K shares. The current price is near the lower end of today's range.
Over the past seven days, Sol-Gel Technologies Ltd. (SLGL) moved from $69.52 to $61.53, representing a decline of 11.49% ($7.99).
The stock traded between $61.00 and $70.99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 44.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 51.3%
SLGL is currently trading at $61.53, placing it 51.3% of the way from its 52-week low of $23.15 to its 52-week high of $97.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sol-Gel Technologies Ltd. (SLGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.